FrancophonIA/ELRC3.0 huggingface dataset:
English: Two medicines are bioequivalent when produce the same levels of the active substance in the body.
Estonian: Kaks ravimit on bioekvivalentsed, kui mõlemad tekitavad organismis sama toimeainesisalduse.
English: It is available as tablets (2.5, 5, 7.5, 10, 15 and 20 mg) and as ‘orodispersible' tablets (5, 10, 15 and 20 mg).
Estonian: Ravimit turustatakse tablettidena (2,5 mg, 5 mg, 7,5 mg, 10 mg, 15 mg ja 20 mg) ja suus dispergeeruvate tablettidena (5 mg, 10 mg, 15 mg ja 20 mg).
English: It is known as an ‘atypical' antipsychotic because it is different from the older antipsychotic medicines that have been available since the 1950s.
Estonian: Toimeainet nimetatakse ebatüüpiliseks antipsühhootikumiks, sest see erineb varasematest, alates 1950. aastatest turustatud antipsühhootikumidest.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Olanzapine Teva on 12 December 2007.
Estonian: Euroopa Komisjon andis Olanzapine Teva müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 12. detsembril 2007.
English: The recommended starting dose of Olanzapine Teva depends on the disease being treated: 10 mg per day is used in schizophrenia and in the prevention of manic episodes, and 15 mg per day in the treatment of manic episodes, unless it is used with other medicines, in which case the starting dose can be 10 mg per day.
Estonian: Olanzapine Teva soovituslik algannus sõltub ravitavast haigusest: skisofreenia korral ja maaniaepisoodide ennetamiseks kasutatakse annust 10 mg ööpäevas ning maaniaepisoodide raviks 15 mg ööpäevas, välja arvatud kasutamisel koos teiste ravimitega, mil algannus võib olla 10 mg ööpäevas.
English: It is thought that olanzapine's beneficial effect is due to it blocking receptors for the neurotransmitters 5-hydroxytryptamine (also called serotonin) and dopamine.
Estonian: Arvatakse, et olansapiini kasulik toime seisneb neurotransmitterite 5-hüdroksütrüptamiini (serotoniin) ja dopamiini retseptorite blokeerimises.
English: It can also be used to prevent the recurrence of these episodes (when symptoms come back) in adults with bipolar disorder (a mental illness causing alternating periods of high mood and depression) who have responded to an initial course of treatment.
Estonian: Seda tohib kasutada ka episoodide kordumise (sümptomite taastekkimise) ennetamiseks bipolaarse meeleoluhäirega (vaimuhaigus, kus vahelduvad meeleolu liigne tõus ja langus) patsientidel, kellel on tekkinud esialgne ravivastus.
English: For more information about treatment with Olanzapine Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Olanzapine Tevaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The orodispersible tablets, which can be used as an alternative to the tablets, are taken by being placed on the tongue, where they disintegrate quickly in the saliva, or by mixing them in water before swallowing.
Estonian: Suus dispergeeruvad tabletid, mida tohib kasutada tavaliste tablettide asemel, asetatakse keelele, kus need süljes kiiresti lagunevad, või segatakse need enne neelamist veega.
English: The Committee recommended that Olanzapine Teva be given marketing authorisation.
Estonian: Komitee soovitas anda Olanzapine Teva müügiloa.
English: Olanzapine Teva olanzapine
Estonian: Olanzapine Teva olansapiin
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Olanzapine Teva.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: This is a summary of the European public assessment report (EPAR) for Olanzapine Teva.
Estonian: See on ravimi Olanzapine Teva Euroopa avaliku hindamisaruande kokkuvõte.
English: Because Olanzapine Teva is a generic medicine and is bioequivalent to the reference medicines, its benefit and risk are taken as being the same as those of the reference medicines.
Estonian: Et Olanzapine Teva on geneeriline ravim ja võrdlusravimitega bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimitel.
English: Its exact mechanism of action is unknown, but it attaches to several receptors on the surface of nerve cells in the brain.
Estonian: Olanzapine Teva täpne toimemehhanism ei ole teada, kuid ravim seondub aju närvirakkude pinnal oleva mitme retseptoriga.
English: The CHMP concluded that, in accordance with EU requirements, Olanzapine Teva has been shown to have comparable quality and to be bioequivalent to Zyprexa and Zyprexa Velotab.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud Olanzapine Teva võrdväärne kvaliteet ja bioekvivalentsus ravimitega Zyprexa ja Zyprexa Velotab.
English: Olanzapine Teva is also effective in maintaining improvement in patients who have responded to an initial course of treatment.
Estonian: Olanzapine Tevat saab kasutada ka esialgse ravivastusega patsientide paranemistulemuse efektiivseks säilitamiseks.
English: What is Olanzapine Teva?
Estonian: Mis on Olanzapine Teva?
English: Other information about Olanzapine Teva
Estonian: Muu teave Olanzapine Teva kohta
English: Olanzapine Teva is also used to treat moderate to severe manic episodes (extremely high mood) in adults.
Estonian: Samuti kasutatakse Olanzapine Tevat täiskasvanutel mõõdukate või raskete maaniaepisoodide (meeleolu äärmuslik tõus) raviks.
English: Olanzapine Teva is a medicine containing the active substance olanzapine.
Estonian: Olanzapine Teva on ravim, mis sisaldab toimeainena olansapiini.
English: Olanzapine Teva is used to treat adults with schizophrenia.
Estonian: Olanzapine Tevat kasutatakse täiskasvanud patsientidel skisofreenia ravimiseks.
English: Because Olanzapine Teva is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicines.
Estonian: Et Olanzapine Teva on geneeriline ravim, piirdusid uuringud katsetega, milles näidati Olanzapine Teva bioekvivalentsust võrdlusravimitega.
English: Why has Olanzapine Teva been approved?
Estonian: Miks Olanzapine Teva heaks kiideti?
English: This means that Olanzapine Teva is similar to ‘reference medicines' already authorised in the European Union (EU) called Zyprexa and Zyprexa Velotab.
Estonian: See tähendab, et Olanzapine Teva on sarnane võrdlusravimitega Zyprexa ja Zyprexa Velotab, millel juba on Euroopa Liidus müügiluba.
English: Olanzapine Teva is a ‘generic medicine'.
Estonian: Olanzapine Teva on geneeriline ravim.
English: The active substance in Olanzapine Teva, olanzapine, is an antipsychotic medicine.
Estonian: Olanzapine Teva toimeaine olansapiin on antipsühhootikum (psühhoosivastane ravim).
English: What are the benefits and risks of Olanzapine Teva?
Estonian: Milles seisneb Olanzapine Teva kasulikkus ja mis riskid Olanzapine Tevaga kaasnevad?
English: How does Olanzapine Teva work?
Estonian: Kuidas Olanzapine Teva toimib?
English: How is Olanzapine Teva used?
Estonian: Kuidas Olanzapine Tevat kasutatakse?
English: How has Olanzapine Teva been studied?
Estonian: Kuidas Olanzapine Tevat uuriti?
English: What is Olanzapine Teva used for?
Estonian: Milleks Olanzapine Tevat kasutatakse?
English: The marketing authorisation holder of SoliCol D3 shall provide evidence that the manufacturing process complies with the requirements of Commission Directive 2003/94/EC laying down the principles and guidelines of Good Manufacturing Practice (GMP) as provided for in Article 8(3) of Directive 2001/83/EC.
Estonian: SoliCol D3 müügiloa hoidja esitab tõestusmaterjali, et tootmisprotsess vastab Euroopa Komisjoni direktiivile 2003/94/EÜ, milles kehtestatakse hea tootmistava põhimõtted ja suunised, nagu on sätestatud direktiivi 2001/83/EÜ artikli 8 lõikes 3.
English: For the suspension of SoliCol D3 to be lifted, the competent authorities shall ensure that the below conditions have been completed by the marketing authorisation holder(s):
Estonian: SoliCol D3 müügilubade peatamise lõpetamiseks peavad pädevad asutused kindlustama, et müügiloa hoidja(d) on täitnud alljärgnevad tingimused.
English: Annex III Conditions for lifting the suspension of the marketing authorisation(s)
Estonian: III lisa Müügiloa (müügilubade) peatamise lõpetamise tingimused
English: What measures are being taken to ensure the safe and effective use of Erelzi?
Estonian: Mis meetmed võetakse, et tagada Erelzi ohutu ja efektiivne kasutamine?
English: Erelzi etanercept
Estonian: Erelzi etanertsept
English: The full EPAR for Erelzi can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Erelzi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: In adults, the usual recommended dose is 25 mg twice a week or 50 mg once a week.
Estonian: Täiskasvanutel on tavaline soovitatav annus 25 mg kaks korda nädalas või 50 mg üks kord nädalas.
English: What is Erelzi and what is it used for?
Estonian: Mis on Erelzi ja milleks seda kasutatakse?
English: The Committee recommended that Erelzi be given marketing authorisation.
Estonian: Komitee soovitas anda Erelzi müügiloa.
English: Over 70% of those given Erelzi (186 of 264 patients) and roughly 72% of those given Enbrel (191 of 267) had at least 75% reduction in their symptom score after 12 weeks of treatment, which was the main measure of effectiveness.
Estonian: Enam kui 70%-l Erelzit saanud patsientidest (186 patsienti 264st) ja ligikaudu 72%-l Enbreli saanud patsientidest (191 patsienti 267st) oli sümptomite skoor pärast 12 ravinädalat vähenenud vähemalt 75% võrra (nende patsientide osakaal oli peamine efektiivsusnäitaja).
English: Erelzi is mostly used when these conditions are severe or moderately severe, or when other treatments have not worked well enough or cannot be used.
Estonian: Erelzit kasutatakse enamasti nende haiguste mõõdukate kuni raskete vormide korral või kui muu ravi ei ole olnud piisavalt efektiivne või muud ravi ei ole võimalik kasutada.
English: The educational materials also include a reminder that Erelzi is not for use in children and adolescents who weigh less than 62.5 kg.
Estonian: Teabematerjalid sisaldavad ka meeldetuletust, et Erelzit ei tohi kasutada alla 62,5 kg kaaluvatel lastel ega noorukitel.
English: The most common side effects with etanercept (seen in more than 1 patient in 10) are injection-site reactions (including bleeding, redness, itching, pain and swelling) and infections (including colds, and lung, bladder and skin infections).
Estonian: Etanertsepti kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on süstekoha reaktsioonid (sh verejooks, punetus, sügelus, valu ja turse) ja infektsioonid (nakkused, sh nohu ning kopsu-, kusepõie- ja nahainfektsioonid).
English: Why is Erelzi approved?
Estonian: Miks Erelzi heaks kiideti?
English: What are the risks associated with Erelzi?
Estonian: Mis riskid Erelziga kaasnevad?
English: Erelzi is not for use in children who need doses other than 25 or 50 mg (e.g. those weighing less than 62.5 kg), because it is only available in these doses; an alternative product should be used in such children.
Estonian: Erelzit ei tohi kasutada lastel, kes vajavad muud annust kui 25 või 50 mg (nt alla 62,5 kg kaaluvad lapsed), kuna ravimit turustatakse vaid nendes annustes; sellistel juhtudel tuleb kasutada muud ravimit.
English: This means that Erelzi is highly similar to a biological medicine (also known as the ‘reference medicine') that is already authorised in the European Union (EU).
Estonian: See tähendab, et Erelzi sarnaneb bioloogilise ravimiga (võrdlusravimiga), millel juba on Euroopa Liidus müügiluba.
English: Erelzi must not be used in patients who have or are at risk of sepsis (when bacteria and toxins circulate in the blood and start to damage the organs), or in patients with active infections.
Estonian: Erelzit ei tohi kasutada patsiendid, kellel on sepsis (kui bakterid ja toksiinid ringlevad veres ning hakkavad kahjustama elundeid) või selle tekkimise risk, või aktiivse infektsiooniga patsiendid.
English: Other information about Erelzi
Estonian: Muu teave Erelzi kohta
English: It is not intended to provide practical advice on how to use Erelzi.
Estonian: Hindamisaruandes ei anta Erelzi kasutamise praktilisi nõuandeid.
English: Therefore, the CHMP's view was that, as for Enbrel, the benefit outweighs the identified risk.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu ka Enbreli korral, ületab Erelzi kasulikkus sellega kaasnevad riskid.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Erelzi have also been included in the summary of product characteristics and the package leaflet.
Estonian: Erelzi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: The company that markets Erelzi will provide educational material for doctors expected to prescribe the product to teach patients how to use the pre-filled pen correctly and a special alert card for patients so they can recognise serious side effects and know when to seek urgent attention from their doctor.
Estonian: Erelzi turustaja tagab ravimit eeldatavasti määravatele arstidele teabematerjali, mis aitab neil õpetada patsiente õigesti kasutama eeltäidetud pensüstalt, ja patsientidele hoiatuskaardi, et nad oskaksid ära tunda raskeid kõrvalnähte ning teaksid, millal on vaja otsekohe arsti poole pöörduda.
English: Because Erelzi is a biosimilar medicine, the studies on effectiveness and safety of etanercept carried out with Enbrel do not all need to be repeated for Erelzi.
Estonian: Et Erelzi on bioloogiliselt sarnane ravim, ei pea Enbreliga tehtud etanertsepti efektiivsuse ja ohutuse uuringuid Erelzi puhul kordama.
English: This is a summary of the European public assessment report (EPAR) for Erelzi.
Estonian: See on ravimi Erelzi Euroopa avaliku hindamisaruande kokkuvõte.
English: Treatment with 50 mg twice a week can also be used during the first 12 weeks of treatment for plaque psoriasis.
Estonian: Naastulise psoriaasi korral tohib manustada ka 50 mg kaks korda nädalas 12 esimese ravinädala jooksul.
English: By blocking TNF, etanercept reduces the inflammation and other symptoms of the diseases.
Estonian: Etanertsept vähendab TNFi blokeerides põletikku ja haiguste muid sümptomeid.
English: How is Erelzi used?
Estonian: Kuidas Erelzit kasutatakse?
English: In children, the dose will depend on body weight.
Estonian: Lastel sõltub annus kehakaalust.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that, in accordance with EU requirements for biosimilar medicines, Erelzi has been shown to have a comparable quality, safety and effectiveness to Enbrel.
Estonian: Inimravimite komitee otsustas, et vastavalt Euroopa Liidu nõuetele bioloogiliselt sarnaste ravimite kohta on tõendatud Erelzi võrreldav kvaliteedi-, ohutus- ja efektiivsusprofiil Enbreli profiiliga.
English: This substance is involved in causing inflammation and is found at high levels in patients with the diseases that Erelzi is used to treat.
Estonian: See aine osaleb põletiku tekitamisel ning selle sisaldus on suur patsientidel, kelle haigusi ravitakse Erelziga.
English: What benefits of Erelzi have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Erelzi kasulikkus?
English: The reference medicine for Erelzi is Enbrel.
Estonian: Erelzi võrdlusravim on Enbrel.
English: Erelzi is an anti-inflammatory medicine for treating the following diseases:
Estonian: Erelzi on põletikuvastane ravim, mis on näidustatud järgmiste haiguste raviks:
English: For more information on biosimilar medicines, see here.
Estonian: Bioloogiliselt sarnaste ravimite lisateave on teabedokumendis siin.
English: Laboratory studies comparing Erelzi with Enbrel have shown that the active substance in Erelzi is highly similar to that in Enbrel in terms of structure, purity and biological activity.
Estonian: Erelzit võrreldi Enbreliga laboriuuringutes, mis tõendasid, et Erelzi toimeaine on struktuuri, puhtuse ja bioloogilise toime poolest Enbreli toimeainega väga sarnane.
English: For practical information about using Erelzi, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Erelzi kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: For more information about treatment with Erelzi, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Erelziga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Studies were carried out to show that Erelzi produces similar levels of the active substance in the body to Enbrel.
Estonian: Viidi läbi uuringud näitamaks, et Erelzi põhjustab organismis samasuguse toimeaine sisalduse kui Enbrel.
English: The active substance in Erelzi, etanercept, is a protein that has been designed to block the activity of a substance called tumour necrosis factor alpha (TNF).
Estonian: Erelzi toimeaine etanertsept on valk, mis blokeerib organismis sisalduva virgatsaine - kasvaja nekroositeguri (TNF) - toime.
English: • psoriatic arthritis (psoriasis with inflammation of the joints) in adults and adolescents;
Estonian: • psoriaatiline artriit (psoriaas koos liigesepõletikuga) täiskasvanutel ja noorukitel;
English: Erelzi was also shown to be as effective as Enbrel in one main study involving 531 adults with plaque psoriasis.
Estonian: Ühes põhiuuringus, milles osales 531 naastulise psoriaasiga täiskasvanut, osutus Erelzi sama efektiivseks kui Enbrel.
English: Treatment is started and supervised by specialised doctors with experience in diagnosing and treating the diseases Erelzi is used for.
Estonian: Ravi Erelziga peab alustama ja jälgima näidustatud haiguste diagnoosimise ja ravi kogemusega eriarst.
English: • rheumatoid arthritis (a disease causing inflammation of the joints) in adults, used with another medicine, methotrexate, or alone;
Estonian: • reumatoidartriit (liigesepõletikku põhjustav haigus) täiskasvanutel, koos metotreksaadiga või ainuravimina;
English: Patients developing a serious infection should stop Erelzi treatment.
Estonian: Raske infektsiooni korral tuleb ravi Erelziga katkestada.
English: • axial spondyloarthritis (a chronic inflammatory disease of the spine) in adults when there are no abnormalities seen on x-ray.
Estonian: • aksiaalne spondüloartriit (krooniline lülisambapõletik) täiskasvanutel, kui röntgeniuuring on leidudeta.
English: For the full list of all side effects reported with Erelzi, see the package leaflet.
Estonian: Erelzi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The injection is given under the skin and the patient or their carer can give the injection if they have been trained appropriately.
Estonian: Ravimit süstitakse naha alla ja pärast asjakohast väljaõpet tohib patsient süstida endale ravimit ise või teeb seda tema hooldaja.
English: Erelzi contains the active substance etanercept and is a ‘biosimilar medicine'.
Estonian: Erelzi sisaldab toimeainena etanertsepti ja on bioloogiliselt sarnane ravim.
English: For detailed information on the use of Erelzi in all conditions, see the summary of product characteristics (also part of the EPAR).
Estonian: Kui vajate lisateavet Erelzi kasutamise kohta nende haiguste korral, lugege palun ravimi omaduste kokkuvõtet (mis on samuti Euroopa avaliku hindamisaruande osa).
English: • certain forms of juvenile idiopathic arthritis (diseases causing inflammation in the joints, with first appearance in childhood or adolescence);
Estonian: • juveniilne idiopaatiline artriit (liigesepõletikku põhjustav haigus, mis algab lapse- või noorukieas)
English: • plaque psoriasis (a disease causing red, scaly patches on the skin) in adults and children;
Estonian: • naastuline psoriaas (punaseid ketendavaid nahalaike põhjustav haigus) täiskasvanutel ja lastel;
English: How does Erelzi work?
Estonian: Kuidas Erelzi toimib?
English: • ankylosing spondylitis (a disease causing inflammation of the joints of the spine) in adults;
Estonian: • anküloseeriv spondüliit (lülisamba liigestes põletikku tekitav haigus) täiskasvanutel;
English: Erelzi is available as prefilled syringes and pens containing a solution for injection.
Estonian: Erelzit turustatakse süstelahust sisaldavates eeltäidetud süstaldes ja pensüstaldes.
English: The medicine can only be obtained with a prescription.
Estonian: Erelzi on retseptiravim.
English: This summary was last updated in October 2016.
Estonian: Kokkuvõtte viimane uuendus: oktoober 2016.
English: VarroMed is irritating to the skin and eyes.
Estonian: VarroMed ärritab nahka ja silmi.
English: Treatment should be given in the late afternoon or evening when bees are less likely to be flying.
Estonian: Ravimit tuleb manustada hilisel pärastlõunal või õhtul, kui mesilased lendavad tõenäoliselt vähem.
English: The full EPAR for VarroMed can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst VarroMedi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: The dose is adjusted to the colony size.
Estonian: Annust kohandatakse vastavalt koloonia suurusele.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that VarroMed's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Veterinaarravimite komitee järeldas, et VarroMedi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas selle kasutamise Euroopa Liidus heaks kiita.
English: The average effectiveness of VarroMed to kill mites (measured by the number of dead mites found at the bottom of the hive) was 88% for winter, 92% for spring and 85% for autumn treatments.
Estonian: VarroMedi keskmine lestade surmamise efektiivsus (mõõdetuna surnud lestade arvu järgi taru põhjas) oli talvel 88%, kevadel 92% ja sügisel 85%.
English: People must not eat, drink or smoke while using the medicine.
Estonian: Veterinaarravimi kasutamise ajal ei tohi süüa, juua ega suitsetada.
English: The effectiveness of VarroMed was investigated in field studies in European countries with different climates, both continental climate and Mediterranean climate.
Estonian: VarroMedi efektiivsust uuriti väliuuringutes, mis tehti erineva (nii kontinentaalse kui ka vahemerelise) kliimaga Euroopa riikides.
English: The European Commission granted a marketing authorisation valid throughout the EU for VarroMed on 2 February 2017.
Estonian: Euroopa Komisjon andis VarroMedi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 02/02/2017.
English: Accidental ingestion may cause adverse reactions.
Estonian: Juhuslik allaneelamine võib põhjustada kahjulikke reaktsioone.
English: In each location 20 test groups were compared to 12 control groups treated with flumethrin (another medicine effective against parasites).
Estonian: Igas uuringukohas võrreldi 20 uuringurühma 12 kontrollrühmaga, mida raviti flumetriiniga (samuti parasiidivastase toimega veterinaarravim).
English: This effect increases with higher doses and/or repeated treatments.
Estonian: See kõrvalnäht võimendub suuremate ja/või korduvate annuste kasutamisel.
English: Varroa mite and honey bee mortality were monitored twice weekly for 4 weeks during treatment until one week after treatment.
Estonian: Varroalestade ja meemesilaste suremust kontrolliti kaks korda nädalas neljanädalase ravi jooksul ja üks nädal pärast ravi lõppu.
English: What is VarroMed and what is it used for?
Estonian: Mis on VarroMed ja milleks seda kasutatakse?